Found: 12
Select item for more details and to access through your institution.
Frequency and Severity of Hypoglycemia Under Conditions of Increased Hypoglycemic Risk with Insulin Efsitora Alfa Versus Insulin Glargine Treatment in Participants with Type 2 Diabetes.
- Published in:
- Diabetes Therapy, 2024, v. 15, n. 8, p. 1785, doi. 10.1007/s13300-024-01605-7
- By:
- Publication type:
- Article
Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist.
- Published in:
- Diabetes Therapy, 2024, v. 15, n. 4, p. 819, doi. 10.1007/s13300-024-01554-1
- By:
- Publication type:
- Article
Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 3, p. 1137, doi. 10.1111/dom.15372
- By:
- Publication type:
- Article
Improvements in post‐challenge lipid response following tirzepatide treatment in patients with type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 2, p. 785, doi. 10.1111/dom.15365
- By:
- Publication type:
- Article
Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1a, blinded, placebo‐controlled, randomized, single‐ and multiple‐ascending‐dose study in healthy participants.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 9, p. 2634, doi. 10.1111/dom.15184
- By:
- Publication type:
- Article
Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 9, p. 2642, doi. 10.1111/dom.15150
- By:
- Publication type:
- Article
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.
- Published in:
- Diabetes Care, 2023, v. 46, n. 5, p. 998, doi. 10.2337/dc22-1710
- By:
- Publication type:
- Article
Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once‐weekly dosing for the treatment of patients with diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 4, p. 1080, doi. 10.1111/dom.14956
- By:
- Publication type:
- Article
20-OR: GPR142 Agonists Increase Glucose-Dependent Insulin Secretion and Differentially Regulate Hormone Secretion in Preclinical and Phase 1 Studies.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-20-OR
- By:
- Publication type:
- Article
Phaeochromocytoma Mimicking Scleroderma.
- Published in:
- International Journal of Endocrinology, 2011, p. 1, doi. 10.1155/2011/917453
- By:
- Publication type:
- Article
Does co-aggregation of the CD45 and CD3 antigens inhibit T cell antigen receptor complex-mediated activation of phospholipase C and protein kinase C?
- Published in:
- European Journal of Immunology, 1992, v. 22, n. 4, p. 1055, doi. 10.1002/eji.1830220427
- By:
- Publication type:
- Article
THE THREONINE REQUIREMENT OF THE NORMAL INFANT.
- Published in:
- Nutrition Reviews, 1977, v. 35, n. 10, p. 275, doi. 10.1111/j.1753-4887.1977.tb06493.x
- By:
- Publication type:
- Article